Brief: Coloplast Keeps 2023/24 Guidance Unchanged

Coloplast A/S

09/02/2024 07:12

Feb 9 (Reuters) - Coloplast A/S  COLOb.CO :
    * INTERIM FINANCIAL REPORT, Q1 2023/24
    * FY 2023/24 - UNCHANGED ORGANIC REVENUE GROWTH AND EBIT
MARGIN
GUIDANCE
    * OUTLOOK FY: REPORTED GROWTH IN DKK IS NOW EXPECTED TO BE
AROUND
11%, FROM PREVIOUSLY AROUND 12%, AND ASSUMES AROUND 1%-POINT
NEGATIVE IMPACT FROM CURRENCIES
    * OUTLOOK FY: IMPACT FROM ACQUISITION OF KERECIS TO REPORTED
GROWTH IS STILL EXPECTED AROUND 4%-POINTS (11 MONTHS).
    * OUTLOOK FY: REPORTED EBIT MARGIN BEFORE SPECIAL ITEMS IS
STILL
EXPECTED TO BE 27-28%.
    * OUTLOOK FY: CAPITAL EXPENDITURES ARE STILL EXPECTED AROUND
DKK
1.4 BILLION. EFFECTIVE TAX RATE IS STILL EXPECTED TO BE AROUND
22%
    * Q1 EBIT MARGIN WAS NEGATIVELY IMPACTED BY THE INFLATIONARY
HEADWINDS ON PRODUCTION COSTS AND THE INCREASE IN OPERATING
EXPENSES, MAINLY DISTRIBUTION COSTS

Source text for Eikon:  ID:nGNE1cXT0S 
Further company coverage:  COLOb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))